Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 4/2006

01-04-2006 | Original Article

PET imaging of brain astrocytoma with 1-11C-acetate

Authors: Ren-Shyan Liu, Cheng-Pei Chang, Lee-Shing Chu, Yum-Kung Chu, Hung-Jen Hsieh, Chi-Wei Chang, Bang-Hung Yang, Shan-Hui Yen, Min-Chao Huang, Su-Quin Liao, Shin-Hwa Yeh

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 4/2006

Login to get access

Abstract

Purpose

The purpose of this study was to assess the use of 1-11C-acetate (ACE) as a metabolic tracer for the detection and characterisation of astrocytomas.

Methods

Positron emission tomography (PET) studies with ACE and 2-18F-fluoro-2-deoxy-D-glucose (FDG) were performed sequentially in 26 patients with primary astrocytomas. Images were analysed by visual interpretation and determination of the tumour to cortex ratio (T/C ratio) and standardised uptake value (SUV). The tumour uptake was visually scored into three grades as compared with the contralateral cortex: clearly lower (–), almost equal (+) and clearly higher (++).

Results

There were 85% of astrocytomas with ++ ACE uptake, 15% with + ACE uptake and none with – ACE uptake. Only 19% of astrocytomas had ++ FDG uptake. Thirty-seven percent of high-grade astrocytomas had + FDG uptake and 37% had – FDG uptake. The sensitivity and specificity of the FDG T/C ratio in discriminating high-grade from low-grade astrocytomas were 79% and 100%, respectively, at the cutoff value of 0.75. Using 2.33 as the cutoff value of the ACE T/C ratio, the sensitivity and specificity were 42% and 86%, respectively. FDG was better than ACE in discriminating high-grade from low-grade astrocytomas. T/C ratios and SUVs of FDG uptake of tumours correlated with the histological grades, but those of ACE uptake did not.

Conclusion

ACE appears to be a promising tracer for use in the detection of primary astrocytomas, but is of limited value in the differentiation of high- and low-grade astrocytomas. ACE is complementary to FDG for the diagnosis and characterisation of astrocytoma.
Literature
1.
Coleman RE, Hoffman JM, Hanson MW, Sostman HD, Schold SC. Clinical application of PET for the evaluation of brain tumors. J Nucl Med 1991;32:616–22PubMed
2.
Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: positron emission tomography. Neurology 1991;41:163–6
3.
Hanson MW, Glantz MJ, Hoffman JM, Friedman AH, Burger PC, Schold SC, et al. FDG-PET in the selection of brain lesions for biopsy. J Comput Assist Tomogr 1991;15:796–801PubMedCrossRef
4.
5.
Larson SM. Cancer or inflammation? A holy grail for nuclear medicine. J Nucl Med 1994;35:1653–55PubMed
6.
Kubota R, Yamada S, Kubota K, Ishiwata K Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992;33:1972–80PubMed
7.
Di Chiro G. Positron emission tomography using [18F]fluorodeoxyglucose in brain tumors: a powerful diagnostic and prognostic tool. Invest Radiol 1986;22:360–71CrossRef
8.
Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, et al. Cerebral gliomas: evaluation with methionine-PET. Radiology 1993;186:45–53PubMed
9.
Buxton DB, Nienaber CA, Luxen A, Ratib O, Hansen H, Phelps ME, et al. Noninvasive quantitation of regional myocardial oxidative metabolism with [1-11C]acetate and dynamic positron emission tomography. Circulation 1989;79:134–42PubMed
10.
Gorelick FS, Tamieson JD. Structure function relationship of the pancreas. In: Johnson LR, ed. Physiology of the gastrointestinal tract. New York: Raven Press; 1981; p. 773–94
11.
Cerdan S, Kunnecke B, Seelig J. Cerebral metabolism of [1,2-13C]acetate as detected by in vivo and in vitro 13C NMR. J Biol Chem 1990;265:12916–26PubMed
12.
Hassel B, Fonnum F. Selective inhibition of glial cell metabolism in vivo by fluorocitrate. Brain Res 1992;576:120–4PubMedCrossRef
13.
Sonnewald U, Westergaard N, Schousboe A, Srendsen J, Unsgärd G, Petersen SB. Direct demonstration by [13C]NMR spectroscopy that glutamine from astrocytes is a precursor for GABA synthesis in neurons. Neuro Chem Int 1993;22:19–29CrossRef
14.
Liu RS, Chang CP, Chu YK, Chu LC, Wu KL, Chou CW, et al. [C-11]acetate positron emission tomography in the detection of brain tumors: comparison with [F-18]fluorodeoxyglucose [abstract]. J Nucl Med 1997;38(suppl):240
15.
Dienel GA, Popp D, Drew PD, Ball K, Krisht A, Cruz NF. Preferential labeling of glial and meningial brain tumors with [2-14C]acetate. J Nucl Med 2001;42:1243–50PubMed
16.
Berl S, Frigyesi TL. Metabolism of [14C]leucine and [14C]acetate in sensorimotor cortex, thalamus, caudate nucleus and cerebellum of the cat. J Neurochem 1968;15:965–70PubMedCrossRef
17.
Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumors of the central nervous system. World Health Organization international classification of tumors. Berlin: Springer; 1993
18.
Pike VW, Eakins MN, Allan RM, Selwyn AP. Preparation of [1-11C]acetate: an agent for the study of myocardial metabolism by positron emission tomography. Int J Appl Radiat Isot 1982;33:505–12PubMedCrossRef
19.
Hamacher K, Coenen HH, Stöcklin G. Efficient stereospecific synthesis of no-carrier-added 2-[18F]fluoro-2-deoxy-D-glucose using amino-polyether supported nucleophilic substitution. J Nucl Med 1986;27:235–8PubMed
20.
Yeh SH, Liu RS, Wu LC, Yen SH, Chang CW, Chen KY. 11C-acetate clearance in nasopharyngeal carcinoma. Nucl Med Commn 1999;20:131–4CrossRef
21.
Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, et al. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 1995;195:47–52PubMed
22.
Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999;26:1501–9PubMedCrossRef
23.
Metz CE, Shen JH. Gains in accuracy from replicated readings of diagnostic images: prediction and assessment in terms of ROC analysis. Med Decis Making 1992;12:60–75PubMedCrossRef
24.
Shields AF, Graham MM, Kozawa SM, Kozell LB, Link JM, Swenson ER, et al. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med 1992;33:581–4PubMed
25.
Cremer JE, Heath DF, Patal AJ, et al. An experimental method of CNS changes associated with chronic liver disease: portocaval anastomosis in the rat. In: Berl S, Clarke DD, Schneider D, eds. Metabolic compartmentation and neurotransmission: relation to brain structure and function. New York: Plenum Press; 1975; p. 461–78
26.
Greenberg HS, Chandler WF, Sandler HM. Brain tumors. New York: Oxford University Press; 1999; p. 58–77
27.
Waniewski RA, Martin DL. Preferential utilization of acetate by astrocytes is attributable to transport. J Neurosci 1998;18:5225–5233PubMed
28.
Shreve P, Chiao PC, Humes D, Schwaiger M, Gross MD. Carbon-11-acetate PET imaging in renal disease. J Ncul Med 1995;36:1595–601
29.
Oyama N, Akino H, Kanamaru H, Suzuki Y, Muramoto S, Yonekura Y, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181–6PubMed
30.
Ho CL, Yu CH, Yeung WC. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213–21PubMed
31.
Würker M, Herholz K, Voges J, Pietrzyk U, Treuer H, Bauer B, et al. Glucose consumption and methionine uptake in low-grade gliomas after iodine-125 brachytherapy. Eur J Nucl Med 1996;23:583–6PubMedCrossRef
32.
Yu HM, Wu CY, Chan PC, et al. A comparative study of 18F-fluoroacetate, 11C-acetate and 18F-FDG in tumor-bearing animal models. J Nucl Med 2005;46(suppl):386
33.
Matthies A, Ezziddin S, Ulrich EM, Palmedo H, Biersack HJ, Bender H, et al. Imaging of prostate cancer metastases with 18F-fluoroacetate using PET/CT. Eur J Nucl Med Mol Imaging 2004;31:797PubMedCrossRef
Metadata
Title
PET imaging of brain astrocytoma with 1-11C-acetate
Authors
Ren-Shyan Liu
Cheng-Pei Chang
Lee-Shing Chu
Yum-Kung Chu
Hung-Jen Hsieh
Chi-Wei Chang
Bang-Hung Yang
Shan-Hui Yen
Min-Chao Huang
Su-Quin Liao
Shin-Hwa Yeh
Publication date
01-04-2006
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 4/2006
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-005-0023-0

Other articles of this Issue 4/2006

European Journal of Nuclear Medicine and Molecular Imaging 4/2006 Go to the issue

Image of the month

The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma

Focus on...

The immune system and cancer: the evolving role of molecular imaging and molecular targeted therapy

Original article

Long-term assessment of striatal dopamine transporters in parkinsonian patients with intrastriatal embryonic mesencephalic grafts

Image of the month

PET/MRI depicts the exact location of meniscal tear associated with synovitis

Original Article

Use of 3′-deoxy-3′-[18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors

Editorial commentary

Molecular imaging of cell transplantation in Parkinson’s disease